RGD engineered dendrimer nanotherapeutic as an emerging targeted approach in cancer therapy

Sheikh, Afsana; Shadab,; Kesharwani, Prashant

doi:10.1016/j.jconrel.2021.10.028

Cited by 77 publications

(33 citation statements)

References 299 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have also been significant developments in siRNA-based drug co-delivery systems. By using polypropylenimine (PPI), a new dendrimer that efficiently transported paclitaxel and a siRNA specific for the CD44 mRNA was synthesized [ 145 , 146 , 147 ]. CD44, a glycoprotein present on the membranes of cancer cells, plays an essential role in cancer development and progression.…”

Section: Drug-delivery System For Ovarian Cancer Treatmentmentioning

confidence: 99%

Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements

Akter

Rahman

Hasan³

et al. 2022

Cells

View full text Add to dashboard Cite

Aggressive and recurrent gynecological cancers are associated with worse prognosis and a lack of effective therapeutic response. Ovarian cancer (OC) patients are often diagnosed in advanced stages, when drug resistance, angiogenesis, relapse, and metastasis impact survival outcomes. Currently, surgical debulking, radiotherapy, and/or chemotherapy remain the mainstream treatment modalities; however, patients suffer unwanted side effects and drug resistance in the absence of targeted therapies. Hence, it is urgent to decipher the complex disease biology and identify potential biomarkers, which could greatly contribute to making an early diagnosis or predicting the response to specific therapies. This review aims to critically discuss the current therapeutic strategies for OC, novel drug-delivery systems, and potential biomarkers in the context of genetics and molecular research. It emphasizes how the understanding of disease biology is related to the advancement of technology, enabling the exploration of novel biomarkers that may be able to provide more accurate diagnosis and prognosis, which would effectively translate into targeted therapies, ultimately improving patients’ overall survival and quality of life.

show abstract

Section: Drug-delivery System For Ovarian Cancer Treatmentmentioning

confidence: 99%

Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements

Akter

Rahman

Hasan³

et al. 2022

Cells

View full text Add to dashboard Cite

show abstract

“…Bone gra materials such as hydroxyapatite and tricalcium phosphate, have been widely used owing to their excellent bioconductivity and biocompatibility. [112][113][114][115][116] However, their use is limited as a bone gra material around implants owing to low strength and fracture toughness. It had been reported that a composite coating of zirconia and hydroxyapatite/ titanium alloy exhibited a complex surface topography at the micro-and nano-structural level, which dramatically enhanced the osteoblastic cell activity and osseointegration.…”

Section: Disadvantages Of Other Biomaterialsmentioning

confidence: 99%

Review on synthesis, properties and multifarious therapeutic applications of nanostructured zirconia in dentistry

et al. 2022

View full text Add to dashboard Cite

show abstract

“…As the free amino group at the surface increases, the loading of RNAitherapeutics also increases. 51 Our group has recently described the process for loading, stabilizing, and delivering siRNA using positively charged dendrimers as the template. 16 Hence, the surface ester groups of dHA were hydrolyzed by adding excess NaOH.…”

Section: Synthesis and Characterization Of Dchamentioning

confidence: 99%

Dendronized Polymeric Biomaterial for Loading, Stabilization, and Targeted Cytosolic Delivery of microRNA in Cancer Cells

Tambe

Patel

Shard

et al. 2022

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are small non-coding RNAs involved in the fine-tuning of gene regulation. Anti-miRNA is a promising RNA-interference (RNAi) agent that potently regulates post-transcriptional expression of an abnormal gene by inhibiting its target mRNAs. To date, ONPATTRO and Leqvio are the only firstin-class USFDA-approved RNAi-therapeutics available in clinic. The deficiency of a fitting delivery carrier remains a primary hindrance to their clinical translation. To address this issue, this investigation reports the development of a dendronized polymeric nanobiomaterial involving a USFDA-approved biopolymer (hyaluronic acid, also called hyaluronan; HA) for the selective delivery of anti-miRNA into the cytosolic compartment of cancer cells. Dendrons are synthesized for focal cationization of HA to produce a cationic dendronized HA polymer (dCHA) using a ligated dendron motif approach. The synthesized dCHA is inert toward blood cells, as observed in the hemolysis assay. It also depicts a strong binding affinity for the CD44-receptor protein and is found to be neutral toward macrophages and albumin proteins (human origin; molecular simulation and docking tool: GROMACS). The developed approach is simple in application, offers high anti-miR21 loading, and avoids RNase enzymatic degradation of loaded anti-miRNA. The dCHA could efficiently escape the lysoendosomal compartment to mediate cytosolic delivery of the loaded anti-miRNA, ascribed to the proton sponge effect offered by weak basic groups of ligated dendron motifs in the dCHA architecture. The dCHA-loaded anti-miR21 upregulates the mRNA levels of Bax and CASP3 and downregulates the levels of Bcl2, accompanied by significant miR21 gene downregulation. Furthermore, under the influence of CD44-receptor blockade, a reduction in the cellular uptake of FAM-labeled anti-miR21 is observed compared to the control, inferring receptor-mediated uptake of dCHA. The conclusive outcome of this research advocates the use of dCHA to be a fit-to-purpose modality to load, preserve, and selectively deliver anti-miRNA-therapeutics to the cytosolic compartment of cancer cells. The developed approach has been tested using anti-miR21 as a model RNAi-therapeutic; however, the knowledge developed in this fundamental research can also be extended to other gene therapeutics, including DNA, siRNA, miRNA mimics, plasmid oligonucleotides, and so forth.

show abstract

RGD engineered dendrimer nanotherapeutic as an emerging targeted approach in cancer therapy

Cited by 77 publications

References 299 publications

Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements

Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements

Review on synthesis, properties and multifarious therapeutic applications of nanostructured zirconia in dentistry

Dendronized Polymeric Biomaterial for Loading, Stabilization, and Targeted Cytosolic Delivery of microRNA in Cancer Cells

Contact Info

Product

Resources

About